ANI Pharma (ANIP) Tops Q3 EPS by 26c ; Offers Guidance

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $1.34, $0.26 better than the analyst estimate of $1.08. Revenue for the quarter came in at $148.3 million versus the consensus estimate of $143.98 million.

GUIDANCE:

ANI Pharma sees FY2024 EPS of $4.90-$5.05, versus the consensus of $4.72. ANI Pharma sees FY2024 revenue of $594-602 million, versus the consensus of $590.3 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Japan's Katayama, Us Treasury's Bessent Hold Online Talks, Source Says - Reuters
• ZenaTech raises Plurilock Security stake to 12% with new share purchase